Skip to main content
SpringerLink
Log in

Escitalopram

A Review of its Use in the Management of Major Depressive Disorder

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Abstract

Escitalopram (Cipralex®, Lexapro™), the active S-enantiomer of the racemic selective serotonin reuptake inhibitor (SSRI) citalopram (RS-citalopram), is a highly selective inhibitor of the serotonin transporter protein. It possesses a rapid onset of antidepressant activity, and is an effective and generally well tolerated treatment for moderate-to-severe major depressive disorder (MDD). Pooled analyses from an extensive clinical trial database suggest that escitalopram is consistently more effective than citalopram in moderate-to-severe MDD. Preliminary studies suggest that escitalopram is as effective as other SSRIs and the extended-release (XR) formulation of the serotonin/noradrenaline (norepinephrine) reuptake inhibitor venlafaxine, and may have cost-effectiveness and cost-utility advantages. However, additional longer-term, comparative studies evaluating specific efficacy, tolerability, health-related quality of life and economic indices would be helpful in definitively positioning escitalopram relative to these other agents in the treatment of MDD. Nevertheless, available clinical and pharmacoeconomic data indicate that escitalopram is an effective first-line option in the management of patients with MDD.

Pharmacological Properties

Unlike other SSRIs, escitalopram appears to not only bind to a primary high-affinity site on the serotonin transporter protein, but also to a secondary, lower-affinity allosteric site that is considered to stabilise and prolong drug binding. In vitro, escitalopram was approximately twice as potent as citalopram in inhibiting serotonin reuptake and, in radioligand binding assays, it was more selective than other SSRIs, including citalopram, for the human serotonin transporter protein. Escitalopram has shown no or very low affinity for various other receptors in vitro. In vivo, escitalopram was four times more potent than citalopram at reducing firing activity of presumed serotonergic neurons in the dorsal raphe nucleus in rat brain.

The multiple-dose pharmacokinetic profile of escitalopram is linear across a 10–30 mg/day dosage (20 mg/day is the maximum approved dosage). Steady-state plasma concentrations are achieved after about 7–10 days’ administration of escitalopram 10 mg/day. The absolute oral bioavailability of escitalopram is about 80%, and protein binding, which is independent of escitalopram plasma concentrations, is ≈55%. Concurrent food ingestion has no influence on escitalopram pharmacokinetics. Escitalopram is extensively metabolised in the liver. In vitro, the cytochrome P450 isoenzymes 2C19, 3A4 and 2D6 contribute equally to its metabolism. The main metabolite is S-demethylcitalopram, which is further metabolised to S-didemethylcitalopram. Both metabolites have virtually no serotonin reuptake activity in vivo. Escitalopram and metabolites are primarily renally excreted, with only a small percentage eliminated as unchanged drug. The plasma elimination half-life is ≈27–33 hours.

Escitalopram dosage adjustments are advocated in elderly patients and those with hepatic impairment, and caution should be exercised with escitalopram use in patients with severe renal impairment.

Therapeutic Efficacy

In well designed, comparative studies with placebo and/or citalopram in patients with moderate-to-severe MDD, escitalopram was more effective than placebo and at least as effective as citalopram in reducing the mean Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline (primary efficacy parameter). In large, pooled analyses in patients with moderate-to-severe MDD, escitalopram was consistently more effective than placebo or citalopram in terms of a faster onset of antidepressant activity, greater decreases in mean MADRS total score and mean Clinical Global Impression-Severity score, and superior rates of response (percentage of patients with a ≥50% decrease in MADRS score) and remission (percentage of patients attaining a MADRS score ≤12).

Several randomised, double-blind studies in patients with moderate-to-severe MDD showed that escitalopram was as effective as paroxetine, sertraline or venlafaxine XR in reducing MADRS scores.

Escitalopram demonstrated continued efficacy in a 52-week open-label extension of two 8-week double-blind studies in primary-care patients with moderate-to-severe MDD, and significantly prevented relapse in 36- and 52-week double-blind, placebo-controlled studies.

Modelled pharmacoeconomic evaluations and a prospective pharmacoeconomic analysis suggested cost-effectiveness advantages for escitalopram relative to several other SSRIs and venlafaxine (including the XR formulation). Cost utility analyses showed that escitalopram dominated all the other treatments. A potential for cost savings (up to 4.5%) was shown in total healthcare budgets for depression when escitalopram is introduced.

Tolerability

In placebo-controlled studies, the most common treatment-emergent adverse events with escitalopram were nausea (15%), ejaculation disorder (9%), insomnia (9%), diarrhoea (8%), somnolence (7%), dry mouth (6%) and dizziness (6%). Nausea led to withdrawal of 2% of patients and 2% of men withdrew because of ejaculation disorder.

Large-scale comparisons of escitalopram with citalopram revealed that the overall type and incidence of adverse events were generally similar between treatments. Escitalopram demonstrated a lower incidence of nausea, increased sweating and constipation than venlafaxine XR. Discontinuation syndrome (Discontinuation Emergent Signs and Symptoms score increase of ≥4) was seen in fewer escitalopram than venlafaxine XR recipients after treatment withdrawal Likewise, in comparisons with paroxetine, fewer escitalopram recipients had discontinuation syndrome after treatment cessation. The tolerability profile of escitalopram was generally similar to that of fluoxetine in elderly patients and to that of sertraline in patients aged 18–80 years.

A large meta-analysis of data from placebo-controlled studies specific to the use of escitalopram revealed that no suicides with the drug occurred within the first 2 weeks or throughout up to 24 weeks of therapy. In addition, MADRS item-10 (‘suicidal thoughts’) scores were reduced compared with placebo from the first week in 8-week studies. Pharmacovigilance data reveal a very low suicide rate of 1.8 per 1 million patients treated with escitalopram.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II
Table III
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Table IV
Fig. 7
Table V

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17(5): 343–62

    Article  PubMed  CAS  Google Scholar 

  2. Croom K, Plosker GL. Escitalopram: a pharmacoeconomic review of its use in depression. Pharmacoeconomics 2003; 21(16): 1185–209

    Article  PubMed  Google Scholar 

  3. Eccles M, Freemantle N, Mason J. North of England evidenced-based guide development project: summary version of guidelines for the choice of antidepressants for depression in primary care. The North of England Anti-depressant Guideline Development Group. Fam Pract 1999; 16(2): 103–11

    CAS  Google Scholar 

  4. Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatment (CANMAT). Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001; 46 Suppl. 1: 1S–92S

    Google Scholar 

  5. Keller MB. The long-term treatment of depression. J Clin Psychiatry 1999; 60 Suppl. 17: 41–5

    PubMed  CAS  Google Scholar 

  6. Kasper S. From symptoms to social functioning: differential effects of antidepressant therapy. Int Clin Psychopharmacol 1999; 14 Suppl. 1: S27–31

    Article  PubMed  Google Scholar 

  7. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18(13): 911–32

    Article  PubMed  Google Scholar 

  8. Fernandez JL, Montgomery S, François C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005; 23(2): 155–67

    Article  PubMed  Google Scholar 

  9. Institute for Clinical Systems Improvement. Health care guideline: major depression in adults in primary care [online]. Available from URL: http://www.isci.org [Accessed 2005 Jul 17]

  10. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical guideline 23. London: National Institute for Clinical Excellence, 2004 Dec

    Google Scholar 

  11. Norman TR, Olver JS. New formulations of existing antidepressants: advantages in the management of depression. CNS Drugs 2004; 18(8): 505–20

    Article  PubMed  CAS  Google Scholar 

  12. Sánchez C, Bergqvist PB, Brennum LT, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl) 2003 Jun; 167(4): 353–62

    Google Scholar 

  13. Forest Laboratories Inc. Lexapro™ (escitalopram oxalate) US prescribing information [online]. Available from URL: http://www.fda.gov [Accessed 2005 Jul 17]

  14. H. Lundbeck AS. Cipralex: European summary of product characteristics [online]. Available from URL: http://www.cipralex.com/images/Cipralex/smpc.pdf [Accessed 2005 Jul 17]

  15. Lundbeck Canada Inc. Annotated prescribing information: escitalopram. Canada: Lundbeck Canada Inc., 2005

    Google Scholar 

  16. Rausch JL, Corley KM, Hobby HM. Improved potency of escitalopram on the human serotonin transporter: demonstration of an ex vivo assay technique. J Clin Psychopharmacol 2004 Apr; 24(2): 209–13

    Article  PubMed  CAS  Google Scholar 

  17. Owens MJ, Knight DL, Nemeroff CB. Second-generation SS-RIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50: 345–50

    Article  PubMed  CAS  Google Scholar 

  18. Chen F, Larsen MB, Sánchez C, et al. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005 Mar; 15(2): 193–8

    CAS  Google Scholar 

  19. Mørk A, Kreilgaard M, Sánchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003 Aug; 45(2): 167–73

    Article  PubMed  Google Scholar 

  20. Storustovu S, Sánchez C, Porzgen P, et al. R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol 2004 May; 142(1): 172–80

    Article  PubMed  CAS  Google Scholar 

  21. Sánchez C, Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 2004 Feb; 77(2): 391–8

    Article  PubMed  Google Scholar 

  22. Mitchell PJ, Hogg S. Behavioral effects of escitalopram predict potent antidepressant activity [abstract no. 401]. Biol Psychiatry 2001; 49 Suppl.: 115S

    Google Scholar 

  23. Nadeem HS, Attenburrow MJ, Cowen PJ. Comparison of the effects of citalopram and escitalopram on 5-HT-mediated neuroendocrine responses. Neuropsychopharmacology 2004 Sep; 29(9): 1699–703

    Article  PubMed  CAS  Google Scholar 

  24. Wingen M, Bothmer J, Langer S, et al. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: a crossover trial. J Clin Psychiatry 2005 Apr; 66(4): 436–43

    Article  PubMed  CAS  Google Scholar 

  25. Sánchez C, Bogeso KP, Ebert B, et al. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004 Jul; 174(2): 163–76

    Article  Google Scholar 

  26. Chen F, Larsen MB, Neubauer HA, et al. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem 2005 Jan; 92(1): 21–8

    Article  PubMed  CAS  Google Scholar 

  27. Sánchez C, Gruca P, Papp M. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behav Pharmacol 2003 Sep; 14(5–6): 465–70

    PubMed  Google Scholar 

  28. El Mansari M, Sánchez C, Chouvet G, et al. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005; 30: 1269–77

    PubMed  Google Scholar 

  29. Ceglia I, Acconcia S, Fracasso C, et al. Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1a receptors. Br J Pharmacol 2004 Jun; 142(3): 469–78

    Article  PubMed  CAS  Google Scholar 

  30. Søgaard B, Mengel H, Rao N, et al. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol. In Press

  31. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001 Aug; 29(8): 1102–9

    Google Scholar 

  32. Areberg J, Christophersen JS, Poulsen MN, et al. Pharmacokinetics of escitalopram in subjects with hepatic impairment [poster]. 8th World Congress of Biological Psychiatry; 2005 Jun 28–Jul 3; Vienna

  33. Malling D, Poulsen MN, Søgaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol 2005; 60(3): 287–90

    Article  PubMed  CAS  Google Scholar 

  34. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003 Apr; 25(4): 1200–10

    Article  PubMed  CAS  Google Scholar 

  35. Preskorn SH, Klick-Davis A, Coyner L, et al. The effect of escitalopram versus sertraline versus duloxetine on CYP 2D6 function [abstract no. NR877 plus poster]. New Research Abstracts. American Psychiatric Association 2005 Annual Meeting; 2005 May 21–26; Atlanta (GA), 326

  36. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005 May; 20(3): 131–7

    Article  PubMed  Google Scholar 

  37. Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003 Jul; 18: 211–7

    Article  PubMed  Google Scholar 

  38. Ninan PT, Ventura D, Wang J. Escitalopram is effective and well-tolerated in the treatment of severe depression [abstract no. NR 486 plus poster]. New Research Abstracts: American Psychiatric Association 2003 Annual Meeting; 2003 May 17–22; San Francisco (CA), 182

  39. Forest Laboratories Inc. SCT-MD-26 [online]. Available from URL: http://forestclinicaltrials.com [Accessed 2005 Sep 6]

  40. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002 Apr; 63(4): 331–6

    Article  PubMed  CAS  Google Scholar 

  41. Wade A, Lemming OM, Hedegaard KB. Escitalopram 10 mg/ day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002 May; 17(3): 95–102

    Article  PubMed  CAS  Google Scholar 

  42. Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Res Med Opin 2005; 21(10): 1659–68

    Article  CAS  Google Scholar 

  43. Vaya L, Appaya PM, Hegde RP, et al. Escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in Indian patients with unipolar depression. Ind J Psychiatry 2004; 46: 333–41

    Google Scholar 

  44. Alexopoulos GS, Gordon J, Zhang D. A placebo-controlled trial of escitalopram and sertraline in the treatment of major depressive disorder [abstract no. 54]. Neuropsychopharmacology 2004; 29 Suppl. 1: 87. Plus poster presented at the 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004 Dec 12–16; San Juan, Puerto Rico

    Article  Google Scholar 

  45. Baldwin D, Hindmarch I, Huusom AKT. Escitalopram and paroxetine in the short and long-term treatment of major depressive disorder (MDD) [abstract no. P01.135]. Int J Neuropsychopharmacol 2004 Jun 22; 7 Suppl. 1: S 168. Plus poster presented at the 24th Congress of the Collegium Internationale Neuropsychopharmacologicum; 2004 Jun 20–24; Paris

    Google Scholar 

  46. Alexopoulos GS, Privitera W, Ventura D, et al. Fixed dose of escitalopram (10 mg/day) and a flexible dosing regimen of sertraline (50–200 mg/day) in a randomised, double-blind comparison in depressed patients [abstract no. 6257]. World J Biol Psychiatry 2004; 5 Suppl. 1: 97.Plus poster presented at the International Congress of Biological Psychiatry; 2004 Feb 9–13; Sydney

    Google Scholar 

  47. Forest Laboratories Inc. SCT-MD-27 [online]. Available from URL: http://forestclinicaltrials.com [Accessed 2005 Sep 12]

  48. Clayton A, Wightman D, Modell JG, et al. Effects in MDD on sexual functioning of bupropion XL, escitalopram, and placebo in depressed patients [abstract no. NR-818 plus poster]. New Research Abstracts. American Psychiatric Association 2005 Annual Meeting; 2005 May 21–26; Atlanta (GA), 303

  49. Wightman D, Horrigan JP, Modell JG, et al. The tolerability and safety of bupropion XL versus escitalopram in the treatment of major depressive disorder [poster]. 13th Congress of the Association of European Psychiatrists (AEP); 2005 Apr 2–6; Munich

  50. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004 Sep; 65(9): 1190–6

    Article  PubMed  CAS  Google Scholar 

  51. Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50(1): 57–64

    Article  PubMed  CAS  Google Scholar 

  52. Rush AJ, Bose A. Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting. Depress Anxiety 2005; 21(1): 26–32

    Article  PubMed  Google Scholar 

  53. Möller HJ, Lotze K, Langer S. postmarketing surveillance of escitalopram in depressed outpatients [abstract no. PO-021.10]. World J Biol Psychiatry 2005; 6 Suppl. 1: 282–283. Plus poster presented at the 8th World Congress of Biological Psychiatry; 2005 Jun 28–Jul 3; Vienna

    Google Scholar 

  54. Zimbroff DL, Bose A, Li D. Escitalopram treatment of SSRI nonresponders can lead to remission in patients who fail initial SSRI therapy [abstract no. NR758 plus poster]. 157th Annual Meeting of the American Psychiatric Association: New Research Abstracts; 2004 May 1–6; New York

  55. Wade A, Despiegel N, Reines EH. Escitalopram in the long-term treatment of major depressive disorder. Ann Clin Psychiatry. In Press

  56. Kornstein SG, Bose A, Li D. Maintenance treatment with escitalopram prevents recurrence of depressive episodes [abstract no. NR744 plus poster]. 157th Annual Meeting of the American Psychiatric Association: New Research Abstracts; 2004 May 1–6; New York, 279–80

  57. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004 Jan; 65(1): 44–9

    Article  PubMed  CAS  Google Scholar 

  58. Llorca PM, Azorin JM, Despiegel N, et al. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005 Mar; 59(3): 268–75

    Article  PubMed  CAS  Google Scholar 

  59. Lepola U, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004 May; 19(3): 149–55

    Article  PubMed  Google Scholar 

  60. Auquier P, Robitail S, Llorca PM, et al. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Pract 2003; 7(4): 259–68

    Article  CAS  Google Scholar 

  61. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials. CNS Spectr 2002 Apr; 7 (4 Suppl. 1): 40–4

    PubMed  Google Scholar 

  62. Wade A, Andersen HF. Onset of effect of escitalopram; a pooled analysis [poster]. 8th World Congress of Biological Psychiatry; 2005 Jun 28–Jul 3; Vienna

  63. Bandelow B, Anderson HF. Escitalopram in the treatment of anxiety associated with depression [poster]. 8th World Congress of Biological Psychiatry; 2005 Jun 28–Jul 3; Vienna

  64. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004 Sep; 19(5): 305–10

    Article  PubMed  Google Scholar 

  65. Lader M, Andersen HF, Baekdal T. The effect of escitalopram on sleep problems in depressed patients. Hum Psychopharmacol 2005; 20: 349–54

    Article  PubMed  CAS  Google Scholar 

  66. Kennedy SH, Anderson EA. Short-term efficacy of escitalopram treatment of MDD: a pooled analysis versus SSRIs and venlafaxine [abstract no. NR873 plus poster]. New Research Abstracts. American Psychiatric Association 2005 Annual Meeting; 2005 May 21–26; Atlanta (GA), 325

  67. Bech P, Tanghoj P, Cialdella P, et al. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 2004 Sep; 7(3): 283–90

    Article  PubMed  CAS  Google Scholar 

  68. Wade AG, Toumi I, Hemels MEH. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005 Apr; 21(4): 631–41

    Article  PubMed  Google Scholar 

  69. Hemels MEH, Kasper S, Walter E, et al. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 2004 Jun; 38(6): 954–60

    Article  PubMed  Google Scholar 

  70. Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005 Apr; 27(4): 486–96

    Article  PubMed  CAS  Google Scholar 

  71. François C, Toumi M, Aakhus AM, et al. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003; 4(1): 12–9

    Google Scholar 

  72. Demyttenaere K, Hemels ME, Hudry J, et al. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005 Jan; 27(1): 111–24

    Article  PubMed  CAS  Google Scholar 

  73. Hemels ME, Kasper S, Walter E, et al. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004 Jun; 20(6): 869–78

    Article  PubMed  Google Scholar 

  74. Löthgren M, Hemels M, François C, et al. A cost-effectiveness analysis of escitalopram as first-line treatment of depression in Sweden. Prim Care Psych 2004; 9(4): 153–61

    Article  Google Scholar 

  75. Hemels M. Probabilistic cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in the Netherlands. 5th World Congress of the International Health Economics Association; 2005 Jul 10–13; Barcelona, 140–1

  76. Armstrong EP, Skrepnek GH, Malone DC, et al. A cost-effectiveness analysis of escitalopram and sertraline in the treatment of major depressive disorder [abstract no. PMH28]. Value Health 2005; 8(3): 393

    Article  Google Scholar 

  77. François C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002; 5: 91–107

    Article  Google Scholar 

  78. Kulp W, Greiner W, Schulenburg JM. Cost-effectiveness of escitalopram vs. venlafaxine XR in the treatment of major depressive disorder in Germany [abstract no. PMH27]. Value Health 2005; 8(3): 392–3. Plus poster presented at ISPOR 10th Annual Meeting; 2005 May 15–18; Washington, DC

    Google Scholar 

  79. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77–87

    Article  PubMed  CAS  Google Scholar 

  80. Baldwin DA, Montgomery SA, Nil R, et al. Discontinuation symptoms in affective disorders [poster]. 8th World Congress of Biological Psychiatry; 2005 Jun 28–Jul 3; Vienna

  81. Kasper S, de Swart H, Anderson HF, et al. Escitalopram in the treatment of depressed elderly patients. Am J Ger Psychiatr. In Press

  82. Gersing K, Taylor L, Mereadith C. Outcomes and adverse events for escitalopram and sertraline in a real-world setting [abstract no. NR815 plus poster]. New Research Abstracts. American Psychiatric Association 2005 Annual Meeting; 2005 May 21–26; Atlanta (GA)

  83. Ashton AK, Mahmood A, Iqbal F. Improvements in SSRI/ SNRI-induced sexual dysfunction by switching to escitalopram. J Sex Marital Ther 2005; 31: 257–62

    Article  PubMed  Google Scholar 

  84. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 2005; 330: 385–8

    Article  PubMed  CAS  Google Scholar 

  85. Pedersen AG. Escitalopram and suicidality in adult depression and anxiety. Int Clin Psychopharmacol 2005 May; 20(3): 139–43

    Article  PubMed  Google Scholar 

  86. Magnuson TM, Burke WJ. Clinical experience with escitalopram, a stereoisomer antidepressant. Todays Ther Trends 2003; 21(2): 117–26

    Google Scholar 

  87. Ellis P. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 2004 Jun; 38(6): 389–407

    PubMed  Google Scholar 

  88. Ashton AK. Reversal of fluoxetine-induced sexual dysfunction by switching to escitalopram [letter]. J Sex Marital Ther 2004; 30: 1–2

    Article  PubMed  Google Scholar 

  89. US Food and Drug Administration. FDA talk paper: FDA reviews data for antidepressant use in adults [online]. Available from URL: http://www.fda.gov/bbs/topics/ANSWERS/2005/ANS01362.html [Accessed 2005 Sep 9]

Download references

Acknowledgements

At the request of the journal, H. Lundbeck A/S provided a non-binding review of this article.

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand

    David Murdoch & Susan J. Keam

Authors
  1. David Murdoch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan J. Keam.

Additional information

Various sections of the manuscript reviewed by: T.R. Einarson, Lesley Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada; G. Guzzo, Lesley Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada; N. Haddjeri, Faculty of Pharmacy, Claude Bernard University, Lyon, France; H. Koponen, Department of Psychiatry, University of Oulu, Oulu, Finland; U. Lepola, Psychiatric Research Clinic of Kuopio, Helsinki and Oulu University, Helsinki, Finland; M. Machado, Lesley Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada; P. Marr, Lesley Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada; T.R. Norman, Department of Psychiatry, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australia.

Data Selection

Sources: Medical literature published in any language since 1980 on escitalopram, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.

Search Strategy: MEDLINE search terms were ‘escitalopram’ and ‘depression’. EMBASE search terms were ‘escitalopram’ and ‘depression’. AdisBase search terms were ‘escitalopram’ or ‘S-citalopram’ and ‘depression’. Searches were last updated 12 October 2005.

Selection: Studies in patients who received escitalopram. Inclusion of studies was based mainly on the methods sections of trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic, pharmacokinetic, and pharmacoeconomic data are also included.

Index Terms: Escitalopram, depression, major depressive disorder, pharmacodynamics, pharmacokinetics, therapeutic efficacy, pharmacoeconomics, tolerability.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murdoch, D., Keam, S.J. Escitalopram. Drugs 65, 2379–2404 (2005). https://doi.org/10.2165/00003495-200565160-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200565160-00013

Keywords

Search

Navigation